Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 3/20 | 0.65 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.65 |
| ▸ | MTNR1A | P48039 | 2/20 | 0.59 |
| ▸ | GFER | P55789 | 1/20 | 0.57 |
| ▸ | MMP9 | P14780 | 1/20 | 0.52 |
| ▸ | AANAT | Q16613 | 1/20 | 0.52 |
| ▸ | TRPV1 | Q8NER1 | 3/20 | 0.52 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.49 |
| ▸ | NPC1 | O15118 | 1/20 | 0.49 |
| ▸ | RAB9A | P51151 | 1/20 | 0.49 |
| ▸ | GSK3B | P49841 | 1/20 | 0.49 |
| ▸ | MAPT | P10636 | 1/20 | 0.49 |
| ▸ | UBE2N | P61088 | 1/20 | 0.49 |
| ▸ | HSD17B2 | P37059 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5658464 | 0.94 | GFER (0.61) | MEN1KMT2AMTNR1AGFERMMP9 | |
| SCHEMBL1233057 | 0.79 | MEN1 (0.83) | MEN1KMT2AMTNR1AGFERMMP9 | |
| SCHEMBL2808670 | 0.78 | MEN1 (0.81) | MEN1KMT2AMTNR1AGFERMMP9 | |
| SCHEMBL12672064 | 0.78 | MEN1 (0.81) | MEN1KMT2AMTNR1AGFERMMP9 | |
| Hydrochloric Acid SCHEMBL6365223 | 0.76 | KMT2A (0.54) | MEN1KMT2AMTNR1AGFERAANAT | |
| SCHEMBL2440677 | 0.76 | MEN1 (0.81) | MEN1KMT2AMTNR1AGFERMMP9 | |
| SCHEMBL23054820 | 0.76 | NPC1 (0.70) | MEN1KMT2AGFERMMP9TRPV1 | |
| SCHEMBL9117842 | 0.76 | MEN1 (0.76) | MEN1KMT2AMTNR1AGFERMMP9 | |
| SCHEMBL5662044 | 0.76 | MEN1 (0.56) | MEN1KMT2AMTNR1AGFERAANAT | |
| SCHEMBL7677886 | 0.75 | MEN1 (0.84) | MEN1KMT2AMTNR1AGFERMMP9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7256194-B2 | Prevent thrombosis; anticholesterol agents; cardiovascular disorders; anticancer agents | MORPHOCHEM (DE) | 2007-08-14 | — | — | US | disclosed |
| EP-1370526-B1 | DIAMIDES WHICH INHIBIT TRYPTASE AND FACTOR XA ACTIVITY | MORPHOCHEM AG KOMB CHEMIE (DE) | 2006-05-24 | — | — | EP | disclosed |
| US-20040082547-A1 | Novel compounds that inhibit factor xa activity | MORPHOCHEM (DE) | 2004-04-29 | — | — | US | disclosed |
| EP-1370526-A1 | DIAMIDES WHICH INHIBIT TRYPTASE AND FACTOR XA ACTIVITY | Morphochem Aktiengesellschaft Für Kombinatorische Chemie (DE) | 2003-12-17 | — | — | EP | disclosed |
| WO-2002068390-A1 | DIAMIDES WHICH INHIBIT TRYPTASE AND FACTOR XA ACTIVITY | Morphochem Aktiengesellschaft für kombinatorische Chemie (DE) | 2002-09-06 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040082547-A1 | Novel compounds that inhibit factor xa activity | F11, TFPI, SERPINC1 | MEN1 625/4885KMT2A 3724/4885MTNR1A 2748/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.